REIC gene therapy - Momotaro-Gene

Drug Profile

REIC gene therapy - Momotaro-Gene

Alternative Names: Ad5-SGE-REIC/Dkk-3; DKK3 gene therapy - Momotaro-Gene; MTG-201; REIC/Dkk-3 gene therapy

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Momotaro-Gene
  • Developer Icahn School of Medicine at Mount Sinai; Momotaro-Gene
  • Class Antineoplastics; Cancer vaccines; Gene therapies
  • Mechanism of Action Apoptosis stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer
  • Preclinical Liver cancer
  • No development reported Cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan (Intratumoural, Injection)
  • 21 Aug 2015 MTG 201 receives Orphan Drug status for Mesothelioma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top